Hypoxic ventilatory response (HVR): Effect of Esketamine

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504229-37-00

Enrollment

Registered

2023-06-12

Start date

2023-08-04

Completion date

2025-03-14

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Brief summary

Hypoxic ventilatory response

Detailed description

Psychomimetic side effects at the end of a hypoxic episode., Esketamine plasma concentrations

Interventions

DRUGRemifentanil-hameln 1 mg

DRUGpoeder voor concentraat voor oplossing voor injectie of infusie

DRUGnormal saline 0.9% NaCl

DRUGNaloxon Orpha 0

DRUG4 mg/ml

DRUGoplossing voor injectie of infusie

DRUGKetanest-S® 5

DRUGoplossing voor injectie 5 mg/ml

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Hypoxic ventilatory response	—

Secondary

Measure	Time frame
Psychomimetic side effects at the end of a hypoxic episode., Esketamine plasma concentrations	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026